Core Insights - Protara Therapeutics reported significant clinical and regulatory advancements for its lead candidate TARA-002, particularly in non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [2][3] - The company is on track to complete enrollment for the BCG-Unresponsive cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 trial for BCG-Naïve patients in the second half of 2026 [1][2] - Financially, Protara completed an oversubscribed public offering raising $86 million, with cash reserves expected to support operations into 2028 [1][9] TARA-002 in NMIBC - TARA-002 demonstrated a complete response (CR) rate of 68% at six months in BCG-Unresponsive patients, with a CR rate of 72.4% in BCG-Naïve patients [1][3] - The Kaplan-Meier estimated probability of maintaining a CR for six months was 71.1% for BCG-Unresponsive patients and 73.1% for BCG-Naïve patients [3][4] - The ADVANCED-2 trial is designed to be registrational based on FDA guidance for BCG-Unresponsive NMIBC [10] TARA-002 in LMs - TARA-002 received Breakthrough Therapy and Fast Track designations from the FDA for the treatment of lymphatic malformations, with a regulatory update expected in the first half of 2026 [1][2][8] - The company is working to expedite the treatment's availability to patients [2] IV Choline Chloride for Patients on Parenteral Support - The THRIVE-3 trial for IV Choline Chloride is ongoing, with interim results anticipated in the second half of 2026 [1][5] - This investigational therapy aims to address choline deficiency in patients dependent on long-term parenteral support [15] Financial Performance - For Q4 2025, Protara reported a net loss of $17.3 million, or $0.37 per share, compared to a net loss of $12.8 million, or $0.48 per share, in Q4 2024 [9][22] - Research and development expenses increased to $13.1 million in Q4 2025 from $9.5 million in the prior year, reflecting the advancement of clinical trials [9][22] - As of December 31, 2025, the company had approximately $198 million in cash and cash equivalents, sufficient to fund operations into 2028 [1][9]

Protara Therapeutics FY Conference Summary Company Overview - **Company**: Protara Therapeutics (NasdaqGM:TARA) - **Lead Program**: TARA-002, a bacterial therapeutic for Non-Muscle Invasive Bladder Cancer (NMIBC) and lymphatic malformations Key Points on TARA-002 and NMIBC - **Mechanism of Action**: TARA-002 is a whole cell bacterial therapeutic engineered to retain antigens while eliminating toxicities associated with traditional treatments. It aims to stimulate a broad immune response without the adverse effects of streptolysin or Streptococcus pyogenes exotoxin [8][10] - **Historical Context**: Originally developed by Chugai Pharmaceutical in the 1970s, TARA-002 (formerly OK-432) has been used in over 65,000 patients in Japan for various cancers, demonstrating significant survival benefits [9][10] - **Current Efficacy Data**: - **BCG-unresponsive Patients**: - 68% complete response (CR) at 6 months, the highest reported in the field [23] - 65% CR at any time [24] - 33% CR at 12 months from a recent update [34] - **BCG-naive Patients**: - 72% CR at any time, 68% CR at 6 months, and 58% CR at 12 months [48] - **Regulatory Pathway**: The FDA has approved a single-arm open-label study for BCG-unresponsive patients, with a focus on CR at 6 months as the primary endpoint [41][57] Competitive Landscape - **Market Positioning**: TARA-002 is positioned as a compelling alternative to existing treatments, with a focus on safety, tolerability, and ease of administration. It is expected to have a significant market share due to its unique mechanism and favorable safety profile [89][92] - **Revenue Potential**: The addressable patient population for TARA-002 is estimated to exceed 20,000 in the frontline plus BCG-exposed settings, which presents a substantial revenue opportunity [41] Lymphatic Malformations Program - **Regulatory Update**: A Type C meeting with the FDA is scheduled, expected to clarify the regulatory path for TARA-002 in treating lymphatic malformations [100] - **Market Opportunity**: The company targets macrocystic and mixed cystic lesions, with an estimated 800 addressable patients annually in the U.S. [110] Choline Program - **Overview**: IV Choline Chloride is aimed at patients on parenteral support, with a significant portion being choline deficient. The FDA has agreed on a pivotal study with a primary endpoint of serum choline elevation [116] Conclusion - Protara Therapeutics is positioned for significant growth with multiple registrational studies underway, focusing on TARA-002 for NMIBC and lymphatic malformations, alongside the choline program. The company emphasizes a strong safety profile, efficacy, and a clear regulatory pathway as key drivers for future success [117][120]

Protara Therapeutics Conference Call Summary Company Overview - **Company**: Protara Therapeutics - **Ticker**: TARA - **Industry**: Biotechnology Key Assets and Development Programs TARA-002 - **Indications**: - Non-muscle invasive bladder cancer (NMIBC) - Lymphatic malformations - **Development Stage**: Late-stage development for both indications [3][4] Mechanism of Action - TARA-002 is a genetically distinct strain of inactivated Streptococcus pyogenes, engineered to retain its immune-stimulating properties [4] - It has been used in Japan for decades as a standard of care for lymphatic malformations and adjunctively with chemotherapy for various cancers [5] Clinical Trials and Data - **ADVANCED-2 Study**: - Focuses on BCG-unresponsive NMIBC patients - Reported a 68% complete response rate at 6 months from 22 patients [9] - Preliminary 12-month complete response rate of 33% from 15 evaluable patients [9] - **ADVANCED-3 Study**: - Aims to utilize TARA-002 in the frontline setting as an alternative to BCG, targeting a significant population due to BCG shortages [6][16] - **STARBORN-1 Study**: - Focused on macrocystic and mixed cystic lymphatic malformations, with ongoing patient enrollment and upcoming FDA engagement for a registrational path [41] Market Opportunity - **Unmet Need**: - Approximately 35% of BCG-eligible patients do not receive BCG due to shortages or intolerance, translating to an annual population of 11,000 to 15,000 patients [25][26] - Potentially addressing tens of thousands of patients annually, including those exposed to BCG [27] - **Competitive Landscape**: - TARA-002 is positioned as a viable alternative in the NMIBC setting, with a focus on ease of use and reliability compared to existing treatments [32] Regulatory Insights - The FDA has indicated that a head-to-head trial against BCG is not necessary, which may facilitate a smoother path to approval [19] Other Programs IV Choline Chloride - **Target Population**: Approximately 35,000 patients in the U.S. on long-term chronic TPN [56] - **Clinical Need**: High prevalence of choline deficiency and liver dysfunction in patients on parenteral nutrition [56] - **Intellectual Property**: Orange Book listed product claim patent extending to 2041, providing exclusivity [62] Financial Considerations - The company is optimistic about pricing strategies based on established benchmarks in the NMIBC setting, allowing flexibility in both NMIBC and lymphatic malformations markets [46] Conclusion - Protara Therapeutics is actively advancing its clinical programs, particularly TARA-002, which addresses significant unmet needs in oncology. The company is well-positioned to capture market share in both NMIBC and lymphatic malformations, with a favorable regulatory outlook and a strong pipeline of assets.

Core Insights - Protara Therapeutics, Inc. is set to present updated interim data from the Phase 2 ADVANCED-2 trial of TARA-002 for BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) at the ASCO Genitourinary Cancers Symposium in February 2026 [1][4] Company Overview - Protara Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases, with TARA-002 as its lead candidate for NMIBC and lymphatic malformations [8] - TARA-002 is an investigational cell therapy derived from genetically distinct group A Streptococcus pyogenes, which has been granted Rare Pediatric Disease Designation by the FDA [5][8] Clinical Trial Details - The ADVANCED-2 trial (NCT05951179) is an open-label Phase 2 study assessing TARA-002 in NMIBC patients, specifically those who are BCG-Unresponsive or BCG-Naïve [3] - Approximately 25 patients will be evaluated for updated safety and efficacy data in the upcoming presentation [2] - The trial includes an induction course of six weekly intravesical instillations of TARA-002, followed by a maintenance course [3] Presentation Information - The poster presentation titled "ADVANCED-2: Interim efficacy and safety data in BCG-Unresponsive participants with high-grade non-muscle invasive bladder cancer" will take place on February 27, 2026 [4] - Another poster titled "Interim safety and tolerability of TARA-002 in patients with BCG-Naïve and Unresponsive high-grade non-muscle invasive bladder cancer in ADVANCED-2" will also be presented on the same day [5] Mechanism of Action - TARA-002 acts as a first-in-class TLR2/NOD2 agonist, activating both innate and adaptive immune pathways within the bladder wall, leading to a pro-inflammatory response and direct tumor cell death [6] Market Context - NMIBC accounts for approximately 80% of bladder cancer diagnoses in the U.S., with around 65,000 new cases diagnosed annually [8]

Core Viewpoint - Protara Therapeutics is a clinical stage biotechnology company focused on developing transformative therapies for rare cancer diseases, with a strong emphasis on oncology and rare diseases [2]. Oncology Focus - The company has two late-stage development programs targeting non-muscle invasive bladder cancer, specifically in BCG-Unresponsive and BCG-Naïve patients [2][4]. - The ADVANCED-2 study is a significant registrational study for BCG-Unresponsive patients with carcinoma in situ, with expectations to complete enrollment before the end of 2026 [4]. Rare Disease Programs - Protara is developing two products in clinical development for rare diseases: - IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral support, currently in Phase III with a pharmacokinetic-based endpoint [3]. - TARA-002, targeting lymphatic malformations for macrocystic and mixed cystic lesions [3]. Company Ambition - Despite its size, Protara demonstrates significant ambition through its diverse portfolio of late-stage development programs in both oncology and rare diseases [4].

Core Insights - Protara Therapeutics is on track to report interim results from approximately 25 six-month evaluable patients in the ADVANCED-2 trial in Q1 2026, focusing on BCG-Unresponsive patients [1][5] - The company has received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs), with a regulatory update expected in the first half of 2026 [1][4] - The first patient has been dosed in the THRIVE-3 registrational trial of IV Choline Chloride, with interim results anticipated in the second half of 2026 [1][7] - Protara completed a public offering of approximately $86 million, extending its cash runway into 2028 [1][8] Protara's Pipeline and Progress - The CEO emphasized the company's commitment to delivering transformative therapies for cancer and rare diseases, highlighting the promising clinical data for TARA-002 in non-muscle invasive bladder cancer (NMIBC) [2] - TARA-002 has shown meaningful and durable activity in BCG-Naïve NMIBC patients, with plans to provide an interim update on the registrational BCG-Unresponsive trial later this quarter [2][5] - Positive results from the Phase 2 STARBORN-1 trial of TARA-002 in LMs have led to FDA designations, with a regulatory update on the path to registration expected in H1 2026 [2][4] Clinical Trials and Manufacturing - Protara is evaluating subcutaneous dosing combined with intravesical dosing for TARA-002 in NMIBC patients, as well as exploring combination treatments [5] - TARA-002 has been selected for the FDA's CMC Development and Readiness Pilot Program, aimed at facilitating manufacturing development for therapies with compressed clinical timelines [6] Financial Update - The recent public offering of approximately $86 million is expected to support Protara's operations and extend its financial runway into 2028 [8]

Core Insights - Protara Therapeutics, Inc. has initiated patient dosing in its Phase 3 THRIVE-3 clinical trial for intravenous Choline Chloride, aimed at patients on long-term parenteral support [1][2] - The company believes that IV Choline Chloride could be the first FDA-approved IV choline therapy for patients dependent on parenteral support, addressing a significant unmet medical need [2][4] Company Overview - Protara Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases, with its lead candidate being TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations [5][6] - The company is also developing IV Choline Chloride as a phospholipid substrate replacement therapy for patients unable to meet their choline needs through oral or enteral nutrition [4][5] Clinical Trial Details - The THRIVE-3 trial is a seamless Phase 2b/3 study designed to evaluate the efficacy and safety of low and high doses of IV Choline Chloride in patients receiving long-term parenteral support [2][3] - Approximately 105 additional patients will be enrolled in a 24-week Phase 3 double-blinded, randomized, placebo-controlled trial, following an 8-week Phase 2b trial involving 24 patients [2][3] Medical Context - Choline deficiency affects 78% of patients on parenteral support, leading to serious health issues, yet there are currently no approved IV choline products available [2][4] - IV Choline Chloride has been granted Fast Track and Orphan Drug Designation by the FDA, highlighting its potential significance in treating choline deficiency in this patient population [4][5]

Company Overview - Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases [3] - The company's lead candidate is TARA-002, an investigational cell-based therapy aimed at treating non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [3] - Protara is conducting an ongoing Phase 2 trial for TARA-002 in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to Bacillus Calmette-Guérin treatment, as well as a Phase 2 trial in pediatric patients with LMs [3] Upcoming Events - Management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 pm PT in San Francisco [1] - A live webcast of the presentation will be available on the company's website, with an archive accessible for a limited time after the event [2] Additional Information - Protara is also developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who cannot meet their choline needs through oral or enteral routes [3]

Core Insights - Protara Therapeutics, Inc. has received Breakthrough Therapy and Fast Track designations from the FDA for TARA-002, an investigational cell-based therapy aimed at treating pediatric patients with lymphatic malformations (LMs) [1][2] - TARA-002 has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, which supports expedited clinical development and earlier patient access [1][4] Company Overview - Protara Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases, with TARA-002 as its lead candidate [7] - The company is also developing IV Choline Chloride for patients on parenteral nutrition [8] Product Details - TARA-002 is a genetically distinct strain of streptococcus pyogenes, inactivated to retain immune-stimulating properties, and has been in clinical use in Japan for 30 years [5] - The therapy has previously received Rare Pediatric Disease designation and has shown significant clinical success in a Phase 2 trial involving over 500 patients [5] Disease Context - Lymphatic malformations are rare congenital conditions affecting lymphatic vessels, often diagnosed in early childhood, with serious complications including airway obstruction and recurrent infections [6]

Core Insights - Protara Therapeutics, Inc. is hosting a conference call and live webcast on December 3, 2025, to discuss new data from an interim analysis of the Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer [1] - The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology, along with updates on FDA feedback regarding the registrational path for TARA-002 [1] Company Overview - Protara Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases [3] - The lead candidate, TARA-002, is an investigational cell-based therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations [3] - Protara is conducting a Phase 2 trial for TARA-002 in NMIBC patients who are unresponsive or naïve to Bacillus Calmette-Guérin treatment, as well as a Phase 2 trial in pediatric patients with lymphatic malformations [3] - The company is also developing IV Choline Chloride, a phospholipid substrate replacement for patients on parenteral nutrition [3]